

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

POLL RESULTS OF THE EGM HELD ON AUGUST 25, 2023

The Board announces that the resolution as set out in the Notice was duly passed by the Shareholders as an ordinary resolution by way of poll at the EGM.

The board of directors (the “**Board**”) of VIVA BIOTECH HOLDINGS (the “**Company**”) is pleased to announce the poll results of the extraordinary general meeting of the Company (the “**EGM**”) held at Meeting Room A615, 735 Ziping Road, Zhoupu Town, Pudong New District, Shanghai, PRC on Friday, August 25, 2023 at 10 a.m.

Reference is made to the Company’s circular (the “**Circular**”) in connection with the EGM and notice of the EGM (the “**Notice**”) dated August 9, 2023. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting result in respect of the resolution proposed at the EGM was as follows:

Ordinary Resolution		Number of Votes (%)	
		For	Against
1.	<p>(a) The Equity Transfer and Capital Injection Agreement, Shareholders Agreement and other Transaction Documents and the Equity Investment as contemplated thereunder be and are hereby approved, confirmed and ratified; and</p> <p>(b) Any one Director be and is hereby authorized to sign, execute and deliver or authorize the signing, execution and delivery of all such documents (including affixing the common seal of the Company thereon) and to do all such things as he or she may in his or her absolute discretion consider necessary, expedient or desirable to implement and/or to give effect to or otherwise in connection with the Equity Transfer and Capital Injection Agreement, Shareholders Agreement and other Transaction Documents and the Equity Investment as contemplated thereunder.</p>	792,194,992 (88.63%)	101,585,405 (11.37%)

Please refer to the Notice for the full text of the resolution proposed at the EGM.

As more than 50% of the votes were cast in favour of each of the above resolution, the resolution was passed as ordinary resolution at the EGM.

The total number of issued Shares as at the date of the EGM was 1,935,036,805 Shares. Pursuant to Rule 17.05A of the Listing Rules, the trustee holding unvested shares of a share scheme, whether directly or indirectly, shall abstain from voting on matters that require shareholders' approval under the Listing Rules, unless otherwise required by law to vote in accordance with the beneficial owner's direction and such a direction is given. Other than Viva Biotech Holdings Restricted Share Unit Scheme, whose trustee shall not exercise the voting rights attached to 19,600,000 Shares held by it, (i) no person was required under the Listing Rules to abstain from voting on the resolution proposed at the EGM and no party has stated its intention in the Circular to vote against or to abstain from voting the resolution proposed at the EGM; (ii) there were no Shares entitling the holders to attend and abstain from voting in favor at the EGM as set out in Rule 13.40 of the Listing Rules; and (iii) there were no restrictions on any Shareholders casting votes on the proposed resolution at the EGM. The total number of Shares entitling the Shareholders to attend and vote on the resolution at the EGM was 1,915,436,805 Shares.

Tricor Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, was appointed as the scrutineer for the vote-taking at the EGM. All Directors attended and participated in the EGM either in-person or by electronic means.

Completion of the Equity Investment is subject to the satisfaction and/or waiver of the conditions precedent therein. In addition, the Equity Transfer and Capital Injection Agreement and the Shareholders Agreement may be terminated in certain circumstances. Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
VIVA BIOTECH HOLDINGS
MAO Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, August 25, 2023

As of the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. Wu Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.